Please assess the completion status of the following clinical trial:

Trial Title: Aggressive Antipyretics for Fever Reduction in CNS Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Evidence of Plasmodium falciparum malaria infection by peripheral blood smear or rapid diagnostic test~* Central nervous system (CNS) symptoms associated with malaria. CEREBRAL MALARIA (CM): Impaired consciousness with a Blantyre Coma Score (BCS)(73) ≤2 in children under 5 years or a Glasgow Coma score (GCS) ≤10 in children ≥5 years OR CNS MALARIA: Complicated seizure(s), meaning prolonged (\>15 minutes), focal or multiple; or impaired consciousness or other evidence of impaired consciousness (confusion, delirium) without frank coma (BCS\>2, GCS =11-14)~Exclusion Criteria:~* Circulatory failure (cold extremities, capillary refill \> 3 seconds, sunken eyes, ↓ skin turgor)~* Vomiting in the past 2 hours~* Serum creatinine (Cr) \> 1.2 mg/dL~* A history of liver disease~* Jaundice or a total bilirubin of \>3.0mg/dL~* A history of gastric ulcers or gastrointestinal bleeding~* A history of thrombocytopenia or other primary hematologic disorder~* Petechiae or other clinical indications of bleeding abnormalities~* A known allergy to ibuprofen, acetaminophen, aspirin or any non-steroidal medication~* Any contraindication for nasogastric tube (NGT) placement and/or delivery of enteral medications

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Aggressive Antipyretics (Type: EXPERIMENTAL): regardless of temperature, children allocated to this arm will receive acetaminophen (30 milligrams (mg)/ kilogram (kg) load then 15mg/kg Q6 hours) and ibuprofen (10mg/kg Q 6 hours) for 72 hours. Pediatric syrup formulations of both agents will be administered orally or via nasogastric tube. For temperatures over 38.5 degrees Celsius, placebo will be added and if the fever persists, a cooling fan will be added.
- Usual Care (Type: PLACEBO_COMPARATOR): will receive placebo for acetaminophen and placebo for ibuprofen. If they have a temperature over 38.5 degrees Celsius, they will receive acetaminophen (15mg/kg, Q6 hours), as needed. If the fever persists, a cooling fan will be added.

Based on this trial design, predict the completion outcome and termination type (if applicable).